R&D News | pharmaphorum

News

Seismic shakes up $121m for AI-designed immunology drugs

Seismic Therapeutics has raised $121 million in second-round financing that will be used to take its two lead drugs through early-stage clinical testing.

News

Merck grabs late-stage oncology drug from China’s Abbisko

Germany’s Merck KGaA is paying Chinese biotech Abbisko Therapeutics $70 million upfront for rights to a drug in phase 3 testing for tenosynovial giant cell tumour (TGCT), a rare disea

News

Pfizer drops twice-daily obesity therapy due to side effects

Pfizer has decided to discontinue the development of another of its experimental obesity therapies, after seeing high rates of discontinuation with the drug in a mid-stage

News

Roche makes obesity play with $2.7bn deal to buy Carmot

Roche has agreed a deal to acquire US biotech Carmot Therapeutics that, if consummated, will thrust it into the increasingly competitive market for incretin-based therapie

News

AstraZeneca links with Absci on AI for biologics discovery

AstraZeneca has agreed a deal worth up to $247 million with US generative artificial intelligence (GenAI) company Absci that will focus on the discovery of a new antibody-

News

MSD, Amgen back patient data specialist Culmination Bio

The venture capital arms of MSD and Amgen have provided $10 million in funding to Culmination Bio, a Utah start-up that aims to build the largest disease-agnostic patient

Seismic shakes up $121m for AI-designed immunology drugs

Merck grabs late-stage oncology drug from China’s Abbisko

Pfizer drops twice-daily obesity therapy due to side effects

Roche makes obesity play with $2.7bn deal to buy Carmot

AstraZeneca links with Absci on AI for biologics discovery

MSD, Amgen back patient data specialist Culmination Bio

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks